Edwards Lifesciences (EW) Payables (2009 - 2026)

Edwards Lifesciences' Payables history runs 18 years deep, the most recent figure standing at $181.1 million for Q1 2026.

• On a quarterly basis, Payables rose 5.05% year-over-year to $181.1 million in Q1 2026; TTM through Mar 2026 was $181.1 million, a 5.05% increase from a year earlier, with the FY2025 full-year figure at $227.5 million, up 15.25% from the prior year.
• Payables fell to $181.1 million in Q1 2026 per EW's latest filing, from $227.5 million in the prior quarter.
• Across five years, Payables topped out at $227.5 million in Q4 2025 and bottomed at $154.9 million in Q3 2022.
• The 5-year median for Payables is $181.1 million (2026), against an average of $182.7 million.
• Across the five-year window, Payables slumped 81.13% in 2022 and increased 23.05% in 2023, its largest moves.
• Year by year, Payables stood at $201.9 million in 2022, then dropped by 7.58% to $186.6 million in 2023, then advanced by 5.79% to $197.4 million in 2024, then grew by 15.25% to $227.5 million in 2025, then slipped by 20.4% to $181.1 million in 2026.
• Per Business Quant, the three latest EW Payables figures stand at $181.1 million (Q1 2026), $227.5 million (Q4 2025), and $165.0 million (Q3 2025).